 Patients receive paclitaxel intravenously IV on days 3, 10, and 17 and imatinib mesylate orally PO once daily QD on days 1-4, 8-11, and 15-18. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity. 